Rachel Gelman, MD
Cornea and External Diseases Specialist · McAllen, TXNPI 1083052658
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $33,600 of the $54,306 with a category attached, or 61.9%. Biotissue Holdings Inc. accounts for 91.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $27,761 and has fallen 97.5% since, to $696 in 2025. Among cornea and external diseases specialist clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 157 payments — averaging $345.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$50K
- Bausch & Lomb Americas Inc.$1K
- Johnson & Johnson Surgical Vision, Inc.$1K
- Alcon$851
- Rxsight Inc$321
- Lensar, Inc.$304
- plus $594 from 9 others
What the payments were for
- Consulting fees$33,60062%
- Speaking & faculty fees$4,2008%
- Travel & lodging$9,26017%
- Food & beverage$7,12513%
- Gifts$1210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 75 | $49,728 |
| Bausch & Lomb Americas Inc. | 14 | $1,485 |
| Johnson & Johnson Surgical Vision, Inc. | 17 | $1,022 |
| Alcon | 19 | $851 |
| Rxsight Inc | 9 | $321 |
| Lensar, Inc. | 4 | $304 |
| Novartis | 3 | $139 |
| AbbVie(2 entities) | 5 | $123 |
| Glaukos Corporation | 3 | $84 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $80 |
| Dompe US, Inc. | 3 | $64 |
| Carl Zeiss Meditec, Inc. | 1 | $36 |
| Eyevance Pharmaceuticals LLC | 1 | $28 |
| Tearlab Corp | 1 | $22 |
| Harrow Eye, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,339
- AmnioGraft$1,339
- enVista Aspire IOL$1,094
- TENEO$1,094
- STELLARIS ELITE$1,094
- VERITAS Vision System$323
- LENSAR LASER SYSTEM$274
- Centurion$150
- LIGHT ADJUSTABLE LENS (LAL) AND LIGHT DELIVERY DEVICE (LDD)$121
- TRYPTYR$115
- enVista MX60 IOL$109
- CATALYS SYSTEM$107
How this compares
$54,306 in reported general payments places this provider in the 90th percentile of 35 cornea and external diseases specialist providers in Texas.
See all cornea and external diseases specialist providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 634 | $29,693 |
| RestasisCyclosporine | 16 | $13,103 |
| MoxifloxacinMoxifloxacin Hcl | 442 | $11,405 |
| Fluorometholone | 101 | $8,307 |
| Cyclosporine | 28 | $6,498 |
| CombiganBrimonidine Tartrate/Timolol | 16 | $4,773 |
| Ketorolac Tromethamine | 215 | $4,462 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,813 |
| ErythromycinErythromycin Base | 191 | $2,291 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 15 | $1,568 |
| Doxycycline Monohydrate | 22 | $966 |
| Latanoprost | 53 | $399 |
| Acyclovir | 20 | $381 |
| Brimonidine Tartrate | 30 | $348 |
| Timolol Maleate | 33 | $309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Combigan | $123 | $17,87632 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $80 | $2,81311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 35 cornea and external diseases specialist providers in Texas.
Other cornea and external diseases specialist in McAllen
- Forrest SwannWaco$111K
- Stella KimHouston$58K
- Ravi PatelRound Rock$9K
- Jeremy BartleyDallas$8K
- Margaret Wang FrenchDallas$5K
- Elizabeth UriasHouston$5K
- Shaam MahasnehMansfield$4K
- Margaret HubbellTexarkana$4K
- Ardalan SharifiGalveston$3K
- Amar BhatBeaumont$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.